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Comparison of Function, Fatigue, Frailty in Patients with
Malignant Hematology, Pre-Bone Marrow Transplant and
Solid Tumors.
Adrian Cristian MD, MHCM1, Marco Ruiz2. 1 Cancer Patient
Support Services, Miami Cancer Institute, Miami, FL; 2 Miami
Cancer Institute, Miami, FL
Introduction: Impaired physical function, fatigue and frailty
are commonly seen in patients undergoing cancer treatment
as well as in cancer survivors. These can have a significant
adverse effect on the quality of life of the affected individuals.
Objectives: To compare the prevalence of impairment of phys-
ical function, fatigue and frailty in three populations of cancer
patients-malignant hematology, patients with malignant
hematology (MH) selected to undergo bone marrow transplant
(pre-BMT) and patients with solid tumors (ST).
Methods: Retrospective chart review of patients referred to a
cancer rehabilitation clinic in a cancer institute. The medical
charts of 355 patients with ST (Breast-264; prostate-20; lung-
34 and GI- 37), 48 patients with MH (AML/ALL-5, Lymphoma-
23, Myeloma-18, other:2) and 29 patients pre-BMT (AML/ALL-
4, Lymphoma-11 and myeloma 14) were reviewed. Mean age:
ST-67, MH-67 and Pre-BMT-55. Gender: ST-305 female;
50male; MH-25 female and 23 male; Pre-BMT-12 female and
17 male. Information reviewed: a) Patient Reported Outcome
Measure Information System (PROMIS) Physical Function short
form and Fatigue short form b) Timed Up and Go (TUG) test c)
Sit to stand in 30 seconds test d) Grip Strength (in Kg), e)
weight loss. Frailty or pre-frailty was determined by using
modified Fried frailty criteria. Elements included: a) exhaus-
tion (PROMIS-Fatigue score) b) low physical activity (PROMIS-
Physical Function score) c) slowness (TUG) d) weakness (Grip
strength) and e) weight loss. If person had 3/5 elements pres-
ent, they were considered “frail” and if 1-2/5 elements were
present, they were considered “pre-frail”.
Results: Impaired physical function: 198/348 of ST patients
(57% ), 35/48 of MH patients (72.9% ) and 9/28 pre-BMT ( 32% ).
Significant Fatigue: 122/349 ST patients (35%), 24/46 of MH
patients (52%) and 6/28 pre-BMT patients (21%). Frail and Pre-
frail: 137/315 (44%) of ST patients met “pre-frail” criteria and
143/315 (45%) ST patients met frail criteria. 14/43 (33%) of MH
patients were “pre-frail” and 27/43 (63%) MH patients were
frail. 16/28 ( 57% ) of pre-BMT patients were “pre-frail” and 7/
28 ( 25% ) pre-BMT patients were frail.
Conclusion:Malignant hematology patients are more likely
to have impaired self-reported physical function,
significant fatigue and be frail compared to patients
selected to undergo BMT and those with solid tumors at
time of initial presentation to a cancer rehabilitation
clinic. Physical impairments, fatigue and frailty should be
identified early at time of diagnosis, during active treat-
ment and during survivorship period and appropriate
rehabilitation interventions initiated to maximize function
and quality of life.
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Ibrutinib for Pure Red Cell Aplasia after Allogeneic
Hematopoietic Stem Cell Transplant with Major ABO
Incompatibility
Shukaib Arslan MD, Anthony S. Stein MD, Stephen J. Forman MD,
Ryotaro Nakamura MD, Monzr M. Al Malki MD. Hematology/
Hematopoietic Cell Transplant, City of Hope National Medical
Center, Duarte, CA
Introduction: Since Human leukocyte antigen (HLA) and
ABO blood group system are inherited independently and
with up to 50% of allogeneic hematopoietic cell transplan-
tations (HCT) are performed with donor-recipient ABO
incompatibility, recipients are at increased risk for acute
and delayed hemolytic reaction and delayed RBC precursors
engraftment; i.e. pure RBC aplasia (PRCA). PRCA is a sever
consequence of major and bi-directional ABO mismatch
after alloHCT, leading to frequent transfusions, iron over-
load and secondary complications. Risk factors for PRCA
after Major ABO incompatibility include; stem cell source,
conditioning intensity, and titer of iso-agglutinins. Treat-
ment is mostly supportive with transfusions and growth
factors as well as withdrawing immunosuppressive therapy
(IS). Targeting recipient immune system with high-dose
steroids, DLI, and rituximab have been reported with vari-
able results. Here we report a case series of a novel method
of targeting recipient iso-agglutinins-producing B cells by
Ibrutinib.
Methods: We report 3 cases of PRCA refractory to conven-
tional therapy who responded to ibrutinib, a BTK inhibitor
targeting recipient B cells to allow engraftment of donor
RBCs. Patient, transplant and disease characteristic includ-
ing prior therapies, time to transfusion independence, and
switch of blood group (BG) are summarized in Table 1. First
patient’s day 30 post-transplant bone marrow biopsy
(BMBx) showed complete remission (CR) with full donor
chimera, but BG remained O. He developed severe anemia
requiring transfusions and Day 100 BMBx showed CR with
markedly decreased number of erythroid progenitors. He
did not respond to IS withdrawal, prednisone, rituximab or
bortezomib. But BMBx 4 weeks after starting ibrutinib
showed trilineage hematopoiesis. Second patient remained
Figure 1. Cumulative incidence of subsequent malignancy after conditioning
with myeloablative fludarabine/busulfan (No TBI group) versus myeloablative
fludarabine/busulfan plus 400 cGy total body irradiation in 2 fractions (TBI
group).
S362 Abstracts / Biol Blood Marrow Transplant 26 (2020) S256S394
